KPS-0373, High dose + KPS-0373, Low dose + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Degeneration
Conditions
Spinocerebellar Degeneration
Trial Timeline
Oct 9, 2013 → Jan 1, 2015
NCT ID
NCT01970098About KPS-0373, High dose + KPS-0373, Low dose + Placebo
KPS-0373, High dose + KPS-0373, Low dose + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Spinocerebellar Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01970098. Target conditions include Spinocerebellar Degeneration.
What happened to similar drugs?
0 of 6 similar drugs in Spinocerebellar Degeneration were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01970098 | Phase 3 | Completed |
Competing Products
15 competing products in Spinocerebellar Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 40 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 40 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 47 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 35 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 40 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 35 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 40 |
| varenicline + placebo | Pfizer | Phase 2 | 35 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 18 |
| IVIG | Baxter | Phase 2 | 32 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 22 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 33 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 32 |
| BHV-4157 | Biohaven | Pre-clinical | 24 |
| troriluzole + Placebo | Biohaven | Phase 3 | 38 |